Drug intelligence / Profile preview

CBE-101

Development stage: Unknown
Lead developer: Cell BioEngines
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CBE-101 (also known as Savi-CORD) is an allogeneic, expanded cord blood-derived hematopoietic stem cell therapy developed by Cell BioEngines. It is designed for patients with hematological malignancies who require a stem cell transplant but lack a suitable human leukocyte antigen (HLA)-matched donor. The therapy utilizes the proprietary Stem-SPACE™ epigenetic regulatory technology to expand hematopoietic stem and progenitor cells (HSPCs) ex vivo while maintaining their stemness and engraftment potential. By providing a significantly higher dose of HSPCs than conventional cord blood units, CBE-101 aims to overcome the common challenges of delayed engraftment and high infection rates associated with traditional cord blood transplantation.

Brand names: Savi-CORD
Other names: Savi-CORD

Beyond the preview

Go deeper on CBE-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBE-101.

Explore the full profile